Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 7/20 | 0.42 |
| ▸ | RNMT | O43148 | 2/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.37 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.37 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.36 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27193644 | 0.95 | TYMP (0.42) | TYMPPRKAG1PRKAA1PRKAB1ADORA1 | |
| SCHEMBL29471806 | 0.92 | TYMP (0.42) | TYMPPRKAG1PRKAA1PRKAB1ADORA1 | |
| SCHEMBL29644745 | 0.92 | TYMP (0.42) | TYMPPRKAG1PRKAA1PRKAB1ADORA1 | |
| SCHEMBL18927153 | 0.92 | TYMP (0.42) | TYMPPRKAG1PRKAA1PRKAB1ADORA1 | |
| SCHEMBL18511052 | 0.92 | TYMP (0.42) | TYMPPRKAG1PRKAA1PRKAB1ADORA1 | |
| SCHEMBL27193642 | 0.92 | TYMP (0.49) | TYMPPRKAG1PRKAA1PRKAB1ADORA1 | |
| SCHEMBL29913291 | 0.89 | TYMP (0.40) | TYMPPRKAG1PRKAA1PRKAB1ADORA1 | |
| SCHEMBL30601047 | 0.88 | TYMP (0.43) | TYMPADORA1 | |
| SCHEMBL29793200 | 0.87 | TYMP (0.42) | TYMPADORA1 | |
| SCHEMBL18822706 | 0.87 | TYMP (0.42) | TYMPPRKAG1PRKAA1PRKAB1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116973-A1 | MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| EP-4277636-A1 | MODIFIED OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| WO-2022155418-A9 | MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2022155418-A1 | MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116973-A1 | MODIFIED OLIGONUCLEOTIDES | ADAR, EIF2AK2, TRDMT1 | TYMP 435/4885RNMT 6/4885PRKAG1 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.